Conditioned Medium from Early-Outgrowth Bone Marrow Cells Is Retinal Protective in Experimental Model of Diabetes
Open Access
- 2 February 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0147978
Abstract
Bone marrow-derived cells were demonstrated to improve organ function, but the lack of cell retention within injured organs suggests that the protective effects are due to factors released by the cells. Herein, we tested cell therapy using early outgrowth cells (EOCs) or their conditioned media (CM) to protect the retina of diabetic animal models (type 1 and type 2) and assessed the mechanisms by in vitro study. Control and diabetic (db/db) mice (8 weeks of age) were randomized to receive a unique intravenous injection of 5×105EOCs or 0.25 ml thrice weekly tail-vein injections of 10x concentrated CM and Wystar Kyoto rats rendered diabetic were randomized to receive 0.50 ml thrice weekly tail-vein injections of 10x concentrated CM. Four weeks later, the animals were euthanized and the eyes were enucleated. Rat retinal Müller cells (rMCs) were exposed for 24 h to high glucose (HG), combined or not with EOC-conditioned medium (EOC-CM) from db/m EOC cultures. Diabetic animals showed increase in diabetic retinopathy (DR) and oxidative damage markers; the treatment with EOCs or CM infusions significantly reduced this damage and re-established the retinal function. In rMCs exposed to diabetic milieu conditions (HG), the presence of EOC-CM reduced reactive oxygen species production by modulating the NADPH-oxidase 4 system, thus upregulating SIRT1 activity and deacetylating Lys-310-p65-NFκB, decreasing GFAP and VEGF expressions. The antioxidant capacity of EOC-CM led to the prevention of carbonylation and nitrosylation posttranslational modifications on the SIRT1 molecule, preserving its activity. The pivotal role of SIRT1 on the mode of action of EOCs or their CM was also demonstrated on diabetic retina. These findings suggest that EOCs are effective as a form of systemic delivery for preventing the early molecular markers of DR and its conditioned medium is equally protective revealing a novel possibility for cell-free therapy for the treatment of DR.Keywords
This publication has 41 references indexed in Scilit:
- SIRT1 Activators Suppress Inflammatory Responses through Promotion of p65 Deacetylation and Inhibition of NF-κB ActivityPLOS ONE, 2012
- SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in miceJournal of Clinical Investigation, 2012
- SIRT1 as a therapeutic target in inflammaging of the pulmonary diseasePreventive Medicine, 2012
- Embryonic stem cell trials for macular degeneration: a preliminary reportThe Lancet, 2012
- The worldwide epidemic of diabetic retinopathyIndian Journal Of Ophthalmology, 2012
- Age Related Changes in NAD+ Metabolism Oxidative Stress and Sirt1 Activity in Wistar RatsPLOS ONE, 2011
- AMP-activated Protein Kinase (AMPK) Negatively Regulates Nox4-dependent Activation of p53 and Epithelial Cell Apoptosis in DiabetesJournal of Biological Chemistry, 2010
- SIRT1 is a redox‐sensitive deacetylase that is post‐translationally modified by oxidants and carbonyl stressThe FASEB Journal, 2010
- Culture-Modified Bone Marrow Cells Attenuate Cardiac and Renal Injury in a Chronic Kidney Disease Rat Model via a Novel Antifibrotic MechanismPLOS ONE, 2010
- Paracrine Mechanisms in Adult Stem Cell Signaling and TherapyCirculation Research, 2008